Cargando…

Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study

Although immune-checkpoint inhibitors (ICIs) have become an important choice of treatment for advanced NSCLC, recent reports show hyperprogressive disease (HPD) after ICI administration. The clinico-pathological features of HPD still remain unclear. Here we report a 65-year-old man with lung adenoca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Yuko, Matsubara, Osamu, Asada, Kazuhiro, Muramatsu, Aya, Suzuki, Makoto, Shirai, Toshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586950/ https://www.ncbi.nlm.nih.gov/pubmed/31249779 http://dx.doi.org/10.1016/j.rmcr.2019.100885

Ejemplares similares

Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab
por: Sama, Shashank, et al.
Publicado: (2019)

Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy
por: Okeya, Komugi, et al.
Publicado: (2019)

Autoimmune pulmonary alveolar proteinosis in a patient with sarcoidosis
por: Tanaka, Yuko, et al.
Publicado: (2019)

Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature
por: Kazemi, Nazanin Yeganeh, et al.
Publicado: (2022)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Hyperprogressive Disease in an Advanced Stage Colon Cancer Patient on Pembrolizumab: A Case Report
por: Chan, Kok Hoe, et al.
Publicado: (2020)

Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer
por: Gu, Yangchun, et al.
Publicado: (2021)

Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma
por: Hu, Chun-Hong, et al.
Publicado: (2022)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Subacute invasive pulmonary aspergillosis after chemoradiotherapy for lung cancer
por: Watanabe, Hirofumi, et al.
Publicado: (2020)

An autopsy case of autoimmune meningoencephalitis caused by pembrolizumab
por: Hiraoka, Yuhi, et al.
Publicado: (2022)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Occupational hypersensitivity pneumonitis in a green tea manufacturer
por: Tanaka, Yuko, et al.
Publicado: (2016)

Pembrolizumab-Induced Meningoencephalitis: A Brain Autopsy Case
por: Minami, Seigo, et al.
Publicado: (2021)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

Longitudinal lung involvement of systemic lupus erythematosus‐related vasculitis and alveolar proteinosis‐like reaction
por: Suzuki, Takahito, et al.
Publicado: (2020)

Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study
por: Zou, Siyi, et al.
Publicado: (2022)

A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
por: Cao, Shuhui, et al.
Publicado: (2022)

Pulmonary cryptococcosis presenting with a large cavity
por: Morita, Satoru, et al.
Publicado: (2014)

Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature
por: Feng, Dongfeng, et al.
Publicado: (2021)

Chronic eosinophilic pneumonia after radiation therapy for squamous cell lung cancer
por: Nakayasu, Hiromasa, et al.
Publicado: (2017)

Nineteen-Month Immunity to Adverse Radiation Effects Following 5-Fraction Re-radiosurgery With 43.6 Gy for Local Progression After Prior 3-Fraction Radiosurgery for Brain Metastasis From Pan-Negative Lung Adenocarcinoma
por: Ohtakara, Kazuhiro, et al.
Publicado: (2023)

Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab
por: Sahin, Ilyas, et al.
Publicado: (2021)

Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment
por: Gao, Yumei, et al.
Publicado: (2023)

Lung Adenocarcinoma with Paraneoplastic Hyper-Eosinophilia Not Responding To Pembrolizumab
por: Wehbe, Hisham, et al.
Publicado: (2021)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
por: Ji, Zhi, et al.
Publicado: (2019)

Sarcoid‐like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Pseudocirrhosis caused by lung adenocarcinoma with diffuse liver metastasis: An autopsy case report
por: Nakano, Sachiko, et al.
Publicado: (2021)

Laryngomalacia presenting as severe uncontrolled asthma
por: Tamura, Kanami, et al.
Publicado: (2018)

Hyperprogression of a spindle‐cell squamous carcinoma of the esophagus after esophagectomy
por: Ji, Yanli, et al.
Publicado: (2022)

Synchronous diffuse large B-cell lymphoma and squamous cell lung carcinoma
por: Fujii, Masato, et al.
Publicado: (2014)

Five-Year Sustained Complete Remission With Minimal Adverse Effects Following Radiosurgery for 2-cm Brain Metastasis With Deep Eloquent Location From Lung Adenocarcinoma Despite Low Marginal Dose and High 12 Gy Volume
por: Ohtakara, Kazuhiro, et al.
Publicado: (2023)

Retroperitoneal Metastasis, with Marked Fibrosis, of Lung Adenocarcinoma after Afatinib Treatment: An Autopsy Case Report
por: Ota, Hiroki, et al.
Publicado: (2020)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
por: Brambilla, Marta, et al.
Publicado: (2020)

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
por: Adashek, Jacob J., et al.
Publicado: (2020)

Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment
por: Kim, Jehun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mj0ojm3ohjj33fvkhspjv8cbch